Myelofibrosis (MF) is myeloproliferative tumor (MPN), which can manifest as primary myelofibrosis (PMF) or secondary MF developed from other MPN, including post polycythemia vera myelofibrosis (post-PV MF) and post-essential thrombocytosis (post ET-MF).
Revive Research Institute is conducting a new study on an investigational drug to better treat patients with malignant myeloid hematologic neoplasms. The two-phase study will assess antitumor effect, safety, and tolerability of the investigational drug in patients with relapsed/refractory acute myeloid leukemia (AML) without standard therapy, or other relapsed/refractory malignant myeloid hematologic neoplasms without standard therapy such as PMF, post-PV MF, or post-ET MF.
- Adults 18 years of age or older, male or female
- Confirmed diagnosis of PMF, post-PV MF, or post-ET MF which failed to standard treatment
- Must have symptomatic splenomegaly
- Must not have undergone a splenectomy or splenic radiation therapy within 6 months prior to screening
Our group of licensed and certified physicians will be keeping track of the patient’s progress throughout the study and will address any concerns or queries that arise regarding the research trial. The investigational treatment is free for the duration of the clinical trial and insurance is not required. All patient records and information will be kept secure and confidential. The patient will also receive compensation for their time and involvement.